Non-Hodgkin's Lymphoma: Current Strategies, Ongoing Challenges, and Future Treatments in Follicular Lymphoma

Faculty : Steven Horwitz, MD. Associate Attending
Memorial Sloan Kettering Cancer Center, New York, NY
Last Modified: May 3, 2013

Share article


Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Upon completion of this activity, participants will be able to: 1)Review recent revisions to NHL treatment guidelines, including updated therapy algorithms, 2) Review the complications associated with treating patients with NHL, and 3) Review the most current data about new therapies, treatment strategies, and combination regimens for NHL.

Continue to Activity


News
Watch & Wait OK in Low-Tumor Burden Follicular Lymphoma

Sep 26, 2012 - An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared with patients initially treated with rituximab-containing regimens, according to research published online Sept. 24 in the Journal of Clinical Oncology.



OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More